SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape

Zhen Wang (), Ruofei Dai, Li Kang, Huan Yang, Zhaosu Chen, Jianzhong He, Lei Shu, Yiting Zhong, Yunfeng Zhang, Zhengyi Hua, Yuanyong Huang, Yuhan Jiang, Jiwen Li, Liyan Xu, Fei Lan (), Shu-Hai Lin () and Jiemin Wong ()
Additional contact information
Zhen Wang: East China Normal University
Ruofei Dai: Fudan University
Li Kang: East China Normal University
Huan Yang: Xiamen University
Zhaosu Chen: East China Normal University
Jianzhong He: Shantou
Lei Shu: East China Normal University
Yiting Zhong: Fudan University
Yunfeng Zhang: East China Normal University
Zhengyi Hua: Xiamen University
Yuanyong Huang: East China Normal University
Yuhan Jiang: Xiamen University
Jiwen Li: East China Normal University
Liyan Xu: Shantou
Fei Lan: Fudan University
Shu-Hai Lin: Xiamen University
Jiemin Wong: East China Normal University

Nature Communications, 2025, vol. 16, issue 1, 1-20

Abstract: Abstract SOX2 is a potent oncodriver for various squamous cancers, but the underlying mechanism is largely unknown. Here we uncover a role of SOX2 in promoting global histone acetylation in esophageal squamous cancer cells (ESCCs). Mechanistic studies reveal that SOX2 promotes global histone acetylation in an AKT-independent manner, and does so by promoting histone acetylation at both SOX2 binding and non-SOX2 binding sites, and accounts for the formation of about half of the super-enhancers. Combined metabolic and transcriptional analyses reveal two mechanisms by which SOX2 enhances global histone acetylation: promoting the expression of multiple histone acetyltransferases and reducing acetyl-CoA consuming fatty acid synthesis in part by repressing the expression of ACSL5. Finally, SOX2 expression correlates negatively with ACSL5 and positively with histone acetylation in clinical esophageal squamous tumors. Altogether, our study uncovers a role of SOX2 in reprogramming lipid metabolism and driving histone hyperacetylation and super-enhancer function, providing mechanistic insights of SOX2 acting as a potent oncodriver.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-63591-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-63591-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-63591-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().